Skip to main content
. 2022 Jun 15;42(11):1318–1327. doi: 10.1093/asj/sjac157

Figure 7.

Figure 7.

Proportion of responders reporting mostly or very satisfied on FLSQ follow-up items at Week 24 (secondary endpoint, mITT populationa). aAll randomized and treated subjects with a baseline and at least 1 postbaseline efficacy assessment, only in the DB phase. *P < 0.05 vs onabotulinumtoxinA 20 U by the Cochran-Mantel-Haenszel test stratified by center. DB, double-blind; FLSQ, Facial Line Satisfaction Questionnaire; mITT, modified intent-to-treat.